1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Verisante Technology, Inc. (VRS) - Product Pipeline Analysis, 2016 Update

Summary

Verisante Technology, Inc. (Verisante), formerly T-Ray Science, Inc., carries out the development and commercialization of products for the early detection of all forms of skin cancer. The company’s key product offerings include Verisante Aura, Verisante Core and Verisante MSI Camera. The Verisante Aura is used for skin cancer detection, and Verisante Core is used for lung, colon and cervical cancer detection. Verisante MSI Camera is a multispectral imaging camera used in the detection of oral and skin cancer. The cancer detection technology helps the company to develop and offer wide range of compact and non-invasive cancer detection devices. The company is ISO 13485:2003 certified as a medical device manufacturer. Verisante is headquartered in Richmond, British Columbia, Canada.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Verisante Technology, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

Verisante Technology, Inc. (VRS) - Product Pipeline Analysis, 2016 Update
Table of Contents
Table of Contents 2


Verisante Technology, Inc. Company Snapshot 6
Verisante Technology, Inc. Company Overview 6
Verisante Technology, Inc. Pipeline Products and Clinical Trials Overview 7
Verisante Technology, Inc. - Pipeline Analysis Overview 9
Business Description 9
Key Facts 9
Verisante Technology, Inc. - Major Products and Services 10
Verisante Technology, Inc. Pipeline Products by Development Stage 11
Verisante Technology, Inc. Pipeline Products Overview 13
ClearVu 13
ClearVu Product Overview 13
ClearVu Elite 14
ClearVu Elite Product Overview 14
Multispectral Imaging (MSI) System 15
Multispectral Imaging (MSI) System Product Overview 15
Verisante Aura 16
Verisante Aura Product Overview 16
Verisante Core - Cervical Cancer 17
Verisante Core - Cervical Cancer Product Overview 17
Verisante Core - Gastro-Intestinal Cancer 18
Verisante Core - Gastro-Intestinal Cancer Product Overview 18
Verisante Core - Lung Cancer 19
Verisante Core - Lung Cancer Product Overview 19
Verisante Core - Nasopharnygeal Cancer 20
Verisante Core - Nasopharnygeal Cancer Product Overview 20
Verisante Technology, Inc. - Key Competitors 21
Verisante Technology, Inc. - Key Employees 22
Verisante Technology, Inc. - Key Employee Biographies 23
Verisante Technology, Inc. - Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Verisante Technology, Inc., Recent Developments 25
Dec 21, 2015: Verisante Provides Operational Update 25
Jul 03, 2015: Verisante Provides Operational Update 25
Mar 12, 2015: Verisante Obtains Mexican Approval 26
Feb 18, 2015: Verisante Technology Announces Equipment Loan to Further Collaboration with Key Chinese Laboratory 26
Oct 01, 2014: Verisante Technology Announces Submission to the FDA for Aura, a Skin Cancer Detection Device 27
Jul 29, 2014: Verisante Technology Welcomes Dr. Kenneth Beer and Dr. Philip Werschler onto Clinical Advisory Board 27
Jun 10, 2014: Verisante Technology Partners with the BC Cancer Foundation to Showcase Aura for Skin Cancer Detection 28
Jun 02, 2014: Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Update 28
May 13, 2014: Verisante Technology Announces Milestone Completion of Core Commercial Prototype for the Detection of Lung Cancer 29
Apr 30, 2014: Verisante Technology Announces 2013 Year End Results and Strategy for Direct Distribution 30
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Verisante Technology, Inc. Pipeline Products and Clinical Trials Overview 7
Verisante Technology, Inc. Pipeline Products by Equipment Type 7
Verisante Technology, Inc. Pipeline Products by Indication 8
Verisante Technology, Inc., Key Facts 9
Verisante Technology, Inc., Major Products and Services 10
Verisante Technology, Inc. Number of Pipeline Products by Development Stage 11
Verisante Technology, Inc. Pipeline Products Summary by Development Stage 12
ClearVu - Product Status 13
ClearVu - Product Description 13
ClearVu Elite - Product Status 14
ClearVu Elite - Product Description 14
Multispectral Imaging (MSI) System - Product Status 15
Multispectral Imaging (MSI) System - Product Description 15
Verisante Aura - Product Status 16
Verisante Aura - Product Description 16
Verisante Core - Cervical Cancer - Product Status 17
Verisante Core - Cervical Cancer - Product Description 17
Verisante Core - Gastro-Intestinal Cancer - Product Status 18
Verisante Core - Gastro-Intestinal Cancer - Product Description 18
Verisante Core - Lung Cancer - Product Status 19
Verisante Core - Lung Cancer - Product Description 19
Verisante Core - Nasopharnygeal Cancer - Product Status 20
Verisante Core - Nasopharnygeal Cancer - Product Description 20
Verisante Technology, Inc., Key Employees 22
Verisante Technology, Inc., Key Employee Biographies 23

List of Figures
Verisante Technology, Inc. Pipeline Products by Equipment Type 8
Verisante Technology, Inc. Pipeline Products by Development Stage 11

Companies Mentioned
STRATA Skin Sciences Inc
SciBase AB
Caliber Imaging and Diagnostics, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.